Late-stage biopharmaceutical company Pharvaris N.V. (PHVS) is heading into the stretch where science meets the scoreboard. The company expects topline results in the fourth quarter of 2025 from RAPIDe-3, its pivotal Phase 3 trial evaluating deucrictibant for the on-demand treatment of HAE attacks.
The study reached target enrollment in March and continues to assess hereditary angioedema (HAE) attacks in enrolled participants. RAPIDe-3 is testing the immediate-release capsule formulation of deucrictibant at a 20 mg dose, which is the intended commercial dosage for acute treatment in adults and adolescents aged 12 and older.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com